Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Compendia: Research Models: APP Mutations
APP-C100

General Information

Transgene: Bgl II-Sma I fragment of APP-695 cDNA (bb 1769-2959) was cloned into a modified form of plasmid pRSV

Promoter: in which the Rous sarcoma virus promoter is replaced with the dystrohpin neural promoter. 

Coding Region:  Transgene is place downstream simian virus 40 splice and polyadenylylation sequences.

Flag Sequence (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys), preceded by a methionine, to the N-terminus of APP-C100

Mouse Strain:  C58BL/6 x SJL. 

Phenotype

Neuropathological Analysis:

As early as 4.5 months of age, APP-C100 mice showed appearance of oddly shaped secondary lysosomes that were immunoreactive with antibodies directed against portions of APP-C100.  In older mice, these structures took the form of abundant deposits of dense, granular material in the hippocampal formation.

Numerous pyramidal cells in various states of degeneration could be found throughout the dentate gyrus and ammon's horn in the 23-month-old and 28-month-old APP-C100 mice, respectively.

At age of 1 year, C100 mice display a significant number of large lucent pyramidal neurons containing irregular cytoplasmic accumulations of atypical secondary lysosomes, and an increased neurofilament concentration in unmyelinated axons.

Cytoskeletal and synaptic degeneration observed in the APP-C100 mice.

FLAG-APP-C100:  The FLAG sequence is used to distinguish the transgene product from the endogenous APP gene product.

FLAGAPP-C100 is less prone to aggregate than was C100, and that it bound with greater affinity than did C100 to a specific PC12 cell receptor that mediates the C100 toxicity, which suggests that C100, unlike Ab, is most deadly to neurons when it is in a nonaggregated form. Also unlike Ab, toxicity of C100 is receptor mediated and pH dependent.

Behavior

No gross motor or sensory abnormalities were apparent in the mice.  

All the mice exhibited normal righting, grasping and placing reflexes.  None of the mice floated excessively during any of the swim trials. No significant differences in Dark-cycle locomotor activities observed between transgenic and control mice.

In Morris water maze,  homozygous transgenic mice expressing Flag epitope-tagged APP-C100, relative to heterozygote Tg and control, showed significant deficits in cued, spatial and reversal performance. The degree of impairment of spatial learning in homozygous mice appears to be age-dependent.

Among heterozygotes, females were relatively more impaired in their spatial learning than were males.

Availibility

Contact Dr. Rachael Neve
202 MRC
McLean Hospital
115 Mill Street
Belmont, MA 02178

Patents:

Patent No. Title Assignee/Inventors Filing Date Issue Date
5,672,805 Transgenic mice expressing the neurotoxic C-terminus of .beta.-amyloid precursor protein The Regents of the University of California/
Neve; Rachael L. 
7/18/91 9/30/97
5,849,999 Transgenic non-human mice expressing Flag-APP-C100 protein develop alzheimer's disease brain morphology and behavior The McLean Hospital Corporation; Wellesley College /
Neve; Rachael L.; Berger-Sweeney; Joanne
10/16/96 12/15/98
5,894,078 Transgenic mouse expressing C-100 app Advanced Bioconcept, Inc./
Nalbantoglu; Josephine; Julien; Jean-Pierre; Shapiro; Matthew
2/26/96 4/13/99

Reference

Primary:

Neve RL, Boyce FM, McPhie DL, Greenan J, Oster-Granite ML. Transgenic mice expressing APP-C100 in the brain. Neurobiol Aging 1996 Mar-Apr;17(2):191-203. Abstract.

Associated:

Oster-Granite ML, McPhie DL, Greenan J, Neve RL. Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J Neurosci 1996 Nov 1;16(21):6732-41. Abstract.

Kammesheidt A, Boyce FM, Spanoyannis AF, Cummings BJ, Ortegon M, Cotman C, Vaught JL, Neve RL. Deposition of beta/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the Alzheimer amyloid precursor in the brain. Abstract.

Berger-Sweeney J, McPhie DL, Arters JA, Greenan J, Oster-Granite ML, Neve RL. Impairments in learning and memory accompanied by neurodegeneration in mice transgenic for the carboxyl-terminus of the amyloid precursor protein. Brain Res Mol Brain Res 1999 Mar 20;66(1-2):150-62. Abstract.


Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark

See recent updates
Alzheimer's Disease Mouse Model Resource
Considerations for Choosing Controls
Research Tools

Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad